CSAG2 and ovarian cancer: On the other side, CSAG2 silencing significantly attenuated the survival advantage conferred by CPEB4 overexpression when treated with paclitaxel, although did not completely reduce to the extent of two vector groups (Figure 5C), at any rate, suggesting that CSAG2 knockdown attenuates CPEB4-mediated paclitaxel resistance in ovarian cancer cells.